Where are you?
  • Austria
  • Belgium
  • Denmark
  • Finland
  • France
  • Germany
  • Guernsey
  • Ireland
  • Italy
  • Jersey
  • Luxembourg
  • Malta
  • Netherlands
  • Norway
  • Portugal
  • Spain
  • Singapore
  • Sweden
  • Switzerland
  • United Kingdom
  • Rest of World
It looks like you’re in
Not your location?
And finally, please confirm the following details
I’m {role} in {country} and I agree to comply with the terms of the website.
You are viewing as from Change

Liontrust Global Alpha Fund

Q2 2022 review
Past performance does not predict future returns. You may get back less than you originally invested. Reference to specific securities is not intended as a recommendation to purchase or sell any investment.

The Liontrust Global Alpha Fund returned -20.9% over the quarter, versus the MSCI AC World Index, which returned -8.6% and its average peer in the IA Flexible Investment sector which returned -6.9% (both comparator benchmarks).

The Liontrust Global Alpha Fund continues to invest in high quality growth stocks that we believe can future proof an investor’s portfolio using the 5 key drivers of Science, Intellectual Property, Deep Technology, Positive Change and Entrepreneurial Vision.

The portfolio allocation is driven by a very substantial overweight in the mid-cap area of the market, as well as a smaller allocation to appropriate large and mega caps to balance the portfolio in areas where we do not see attractive mid-cap companies. This overweight of mid-cap companies, that range between $10bn-$30bn market capitalisation is designed to help identify those stocks that can grow quickly to a $50bn-$250bn and beyond. The Fund does not have direct holding in small cap stocks, those below $10bn and invests solely in equities, having zero allocation to bonds or property.

We continue to believe that active and disciplined stock selection can deliver sustained outperformance, shown by the long-term performance of the Fund, which has returned 664.2% since its launch versus the IA peer group 344.1%.

Over the more recent term, prevailing conditions continue to offer considerable headwinds for our investment approach, with central banks around the world still raising interest rates to curb inflation. For companies where the market expects growth for years to come, a large proportion of the valuation is attributed to cash flows in the future (known as long duration); conversely, for stocks with lower expectations, less value is ascribed to future growth and the bulk of the value is in near-term cash flows.

Companies with strong growth expectations, therefore, have higher sensitivity to interest rate changes than those with lower growth prospects, with the market discounting future earnings more heavily and bringing down their present valuation as a result. This shift has hit the fund hard given its bias to high quality growth stocks and longer duration relative to the market.

Among the notable positive contributors was multinational pharmaceutical and biotechnology company Pfizer. In terms of company news over the three months, Pfizer announced it will acquire Biohaven Pharmaceutical Holding Co. for $11.6 billion in cash to gain an approved treatment for migraine headaches. With billions in hand from sales of its Covid-19 vaccine and treatment, Pfizer has the resources to diversify beyond pandemic products that may have limited demand as the outbreak winds down.

Brown-Forman was another contributor in a difficult period for the Fund, with the American wine and spirits business posting robust financial results for fourth quarter and fiscal year ended 30 April 2022. For the fourth quarter, the company’s reported net sales of $996 million increased 23%, with reported operating income also increasing 46% to $246 million and diluted earnings per share increased 26% to $0.31. For the full year, the company’s reported net sales increased 14% to $3,933 million.

Like the rest of technology, shares in Nvidia have been hurt as the fastest rise in inflation in decades is triggering a global cycle of higher interest rates. That has hit first and foremost, the high- growth, high-multiple tech companies, in software and consumer services. But the stock selloff is also affecting the more cyclical chip business, on the perceived view that demand for industrial and consumer goods will suffer as rising rates threaten to tip the economy into a recession.

In addition, China’s Covid-19 lockdowns and the war in Ukraine weighed on Nvidia’s sales forecast. The outlook reflects the continuing supply-chain chaos in China, where Covid-19 lockdowns have disrupted production and transportation lines. That has made it harder for companies like Nvidia to capitalize on still-growing demand for chips. Nvidia also cited Russia, which invaded Ukraine and drew widespread sanctions earlier this year, for hurting its outlook.

Also among the impacted semiconductor stocks was ASML, which sells the machines that make semiconductors and is the world’s largest supplier of photolithography systems, the standard method of printed circuit board (PCB) and microprocessor fabrication.

Despite posting solid results over the quarter, Cloudflare fell sharply. For the quarter ended March 31, Cloudflare reported a profit before costs of $3.5 million, or one cent per share, compared with a loss of $9.3 million, or three cents per share, in the same quarter of 2021. Revenue jumped 54%, to $212.2 million.

Looking forward, Cloudflare predicts adjusted earnings of breakeven to a loss of a penny a share in the second quarter on revenue of $226.5 million to $227.5 million. The stock's share price decline comes as the market is rerating growth stocks like Cloudflare lower. However, we believe the company continues to execute at an impressive rate on its promise to build a better internet with incredible speed of product innovation in areas ranging from website DDOS protection to Cloud Deployment tool and its prospects remain fairly unchanged, however its market rating (multiple) has been severely hammered in this environment.

We continue to be positive on the outlook for high quality growth stocks over the next year. We are especially positive as the mid cap area of the market continues to give considerable scope for further outperformance as the world continues to recover from the Covid-19 pandemic. Our emphasis on the drivers of Science, Intellectual Property, Deep Technology, Positive Change and Entrepreneurial Vision will, we believe, guide the Fund towards those companies that will change the world as we adapt going forward.

Discrete years' performance (%), to previous quarter-end:







Liontrust Global Alpha C Acc












IA Flexible Investment













*Source: FE Analytics as at 30.06.22


**Source: FE Analytics as at 30.06.22. Quartile generated on 06.07.22

Understand common financial words and terms See our glossary

Past performance is not a guide to future performance. The value of an investment and the income generated from it can fall as well as rise and is not guaranteed. You may get back less than you originally invested.

The issue of units/shares in Liontrust Funds may be subject to an initial charge, which will have an impact on the realisable value of the investment, particularly in the short term. Investments should always be considered as long term.

Investment in the Fund involves foreign currencies and may be subject to fluctuations in value due to movements in exchange rates. The Fund may invest in emerging markets/soft currencies or in financial derivative instruments, both of which may have the effect of increasing volatility. 


This is a marketing communication. Before making an investment, you should read the relevant Prospectus and the Key Investor Information Document (KIID), which provide full product details including investment charges and risks. These documents can be obtained, free of charge, from www.liontrust.co.uk or direct from Liontrust. Always research your own investments. If you are not a professional investor please consult a regulated financial adviser regarding the suitability of such an investment for you and your personal circumstances.

This should not be construed as advice for investment in any product or security mentioned, an offer to buy or sell units/shares of Funds mentioned, or a solicitation to purchase securities in any company or investment product. Examples of stocks are provided for general information only to demonstrate our investment philosophy. The investment being promoted is for units in a fund, not directly in the underlying assets. It contains information and analysis that is believed to be accurate at the time of publication, but is subject to change without notice. Whilst care has been taken in compiling the content of this document, no representation or warranty, express or implied, is made by Liontrust as to its accuracy or completeness, including for external sources (which may have been used) which have not been verified. It should not be copied, forwarded, reproduced, divulged or otherwise distributed in any form whether by way of fax, email, oral or otherwise, in whole or in part without the express and prior written consent of Liontrust.

Global Equities

Related commentaries

See all related
Fund updates
Liontrust Global Alpha Fund Q1 2024 review
icon 8 May 2024
Liontrust Global Equities Team
Fund updates
Liontrust Global Alpha Fund Q4 2023 review
icon 17 January 2024
Liontrust Global Equities Team
Fund updates
Liontrust Global Alpha Fund Q2 2023 review
icon 26 July 2023
Liontrust Global Equities Team
Fund updates
Liontrust Global Alpha Fund Q1 2023 review
icon 25 April 2023
Commentaries Global Equity
Fund updates
Liontrust Global Alpha Fund Q4 2022 review
icon 30 January 2023
Global Equity
Fund updates
Liontrust Global Alpha Fund Q3 2022 review
icon 24 October 2022
Commentaries Global Equity